{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:11:46Z","timestamp":1784740306195,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82373044"],"award-info":[{"award-number":["No. 82373044"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Shandong Province","award":["No. ZR2022LSW001"],"award-info":[{"award-number":["No. ZR2022LSW001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-23874-3","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:11:53Z","timestamp":1763413913000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of efficacy and safety of first-line immunotherapy combined with chemotherapy in extensive-stage small cell lung cancer, a retrospective study"],"prefix":"10.1038","volume":"15","author":[{"given":"Xue","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yintao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"23874_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA. Cancer J. Clin. 74, 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"Cancer J. Clin."},{"key":"23874_CR2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.mcna.2018.12.006","volume":"103","author":"F Nasim","year":"2019","unstructured":"Nasim, F., Sabath, B. F. & Eapen, G. A. Lung cancer. Med. Clin. North Am. 103, 463\u2013473. https:\/\/doi.org\/10.1016\/j.mcna.2018.12.006 (2019).","journal-title":"Med. Clin. North Am."},{"key":"23874_CR3","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.neo.2017.07.007","volume":"19","author":"B Oronsky","year":"2017","unstructured":"Oronsky, B., Reid, T. R., Oronsky, A. & Carter, C. A. What\u2019s new in SCLC? A review. Neoplasia 19, 842\u2013847. https:\/\/doi.org\/10.1016\/j.neo.2017.07.007 (2017).","journal-title":"Neoplasia"},{"key":"23874_CR4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","volume":"17","author":"AG Nicholson","year":"2022","unstructured":"Nicholson, A. G. et al. The 2021 WHO classification of lung tumors: Impact of advances since 2015. J. Thorac. Oncol. 17, 362\u2013387. https:\/\/doi.org\/10.1016\/j.jtho.2021.11.003 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"23874_CR5","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1002\/ijc.34346","volume":"152","author":"Y Yu","year":"2023","unstructured":"Yu, Y., Chen, K. & Fan, Y. Extensive-stage small-cell lung cancer: Current management and future directions. Int. J. Cancer 152, 2243\u20132256. https:\/\/doi.org\/10.1002\/ijc.34346 (2023).","journal-title":"Int. J. Cancer"},{"key":"23874_CR6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nrc.2017.87","volume":"17","author":"AF Gazdar","year":"2017","unstructured":"Gazdar, A. F., Bunn, P. A. & Minna, J. D. Small-cell lung cancer: What we know, what we need to know and the path forward. Nat. Rev. Cancer 17, 725\u2013737. https:\/\/doi.org\/10.1038\/nrc.2017.87 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"23874_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/JCO.21.01881","volume":"40","author":"J Zugazagoitia","year":"2022","unstructured":"Zugazagoitia, J. & Paz-Ares, L. Extensive-Stage small-cell lung cancer: First-line and second-line treatment options. J. Clin. Oncol. 40, 671\u2013680. https:\/\/doi.org\/10.1200\/JCO.21.01881 (2022).","journal-title":"J. Clin. Oncol."},{"key":"23874_CR8","doi-asserted-by":"publisher","first-page":"1126582","DOI":"10.3389\/fimmu.2023.1126582","volume":"14","author":"J He","year":"2023","unstructured":"He, J. & Hu, Q. Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer. Front. Immunol. 14, 1126582. https:\/\/doi.org\/10.3389\/fimmu.2023.1126582 (2023).","journal-title":"Front. Immunol."},{"key":"23874_CR9","doi-asserted-by":"publisher","unstructured":"A. Ortega-Franco, C. Ackermann, L. Paz-Ares, R. Califano, First-line immune check-point inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions, ESMO Open 6 (2021) 100003. https:\/\/doi.org\/10.1016\/j.esmoop.2020.100003.","DOI":"10.1016\/j.esmoop.2020.100003."},{"key":"23874_CR10","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","volume":"19","author":"AKP Ganti","year":"2021","unstructured":"Ganti, A. K. P. et al. Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 19, 1441\u20131464. https:\/\/doi.org\/10.6004\/jnccn.2021.0058 (2021).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"23874_CR11","doi-asserted-by":"publisher","first-page":"113581","DOI":"10.1016\/j.ejca.2024.113581","volume":"200","author":"I Gomez-Randulfe","year":"2024","unstructured":"Gomez-Randulfe, I., Leporati, R., Gupta, B., Liu, S. & Califano, R. Recent advances and future strategies in first-line treatment of ES-SCLC. Eur. J. Cancer 200, 113581. https:\/\/doi.org\/10.1016\/j.ejca.2024.113581 (2024).","journal-title":"Eur. J. Cancer"},{"key":"23874_CR12","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3390\/cancers13030506","volume":"13","author":"SK Wong","year":"2021","unstructured":"Wong, S. K. & Iams, W. T. Front line applications and future directions of immunotherapy in small-cell lung cancer. Cancers 13, 506. https:\/\/doi.org\/10.3390\/cancers13030506 (2021).","journal-title":"Cancers"},{"key":"23874_CR13","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3389\/fonc.2020.01074","volume":"10","author":"A Saltos","year":"2020","unstructured":"Saltos, A., Shafique, M. & Chiappori, A. Update on the biology, management, and treatment of small cell lung cancer (SCLC). Front. Oncol. 10, 1074. https:\/\/doi.org\/10.3389\/fonc.2020.01074 (2020).","journal-title":"Front. Oncol."},{"key":"23874_CR14","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu, S. V. et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J. Clin. Oncol. 39, 619\u2013630. https:\/\/doi.org\/10.1200\/JCO.20.01055 (2021).","journal-title":"J. Clin. Oncol."},{"key":"23874_CR15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.annonc.2019.10.021","volume":"31","author":"AS Mansfield","year":"2020","unstructured":"Mansfield, A. S. et al. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): A randomized phase I\/III trial. Ann. Oncol. 31, 310\u2013317. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.021 (2020).","journal-title":"Ann. Oncol."},{"key":"23874_CR16","doi-asserted-by":"crossref","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. The Lancet. 2019;394(10212):1929\u20131939. doi:10.1016\/S0140-6736(19)32222-6","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"23874_CR17","doi-asserted-by":"crossref","unstructured":"Goldman, J.W., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D. et al. Durvalumab, with or without tremelimumab, plus platinum\u2013etoposide versus platinum\u2013etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncology. 22(1), 51\u201365. doi:10.1016\/S1470-2045(20)30539-8 (2021).","DOI":"10.1016\/S1470-2045(20)30539-8"},{"key":"23874_CR18","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","volume":"23","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23, 739\u2013747. https:\/\/doi.org\/10.1016\/S1470-2045(22)00224-8 (2022).","journal-title":"Lancet Oncol."},{"key":"23874_CR19","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.semcancer.2022.02.021","volume":"86","author":"ED Barrows","year":"2022","unstructured":"Barrows, E. D., Blackburn, M. J. & Liu, S. V. Evolving role of immunotherapy in small cell lung cancer. Semin. Cancer Biol. 86, 868\u2013874. https:\/\/doi.org\/10.1016\/j.semcancer.2022.02.021 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"23874_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamaoncol.2022.5631","volume":"9","author":"WJ Petty","year":"2023","unstructured":"Petty, W. J. & Paz-Ares, L. Emerging strategies for the treatment of small cell lung cancer: A review. JAMA Oncol. 9, 419. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5631 (2023).","journal-title":"JAMA Oncol."},{"key":"23874_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.lungcan.2023.02.003","volume":"178","author":"S Wang","year":"2023","unstructured":"Wang, S. et al. Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis. Lung Cancer Amst. Neth. 178, 47\u201356. https:\/\/doi.org\/10.1016\/j.lungcan.2023.02.003 (2023).","journal-title":"Lung Cancer Amst. Neth."},{"key":"23874_CR22","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares, L. et al. Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial. Lancet 394, 1929\u20131939. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6 (2019).","journal-title":"Lancet"},{"key":"23874_CR23","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"328","author":"Y Cheng","year":"2022","unstructured":"Cheng, Y. et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: The ASTRUM-005 randomized clinical trial. JAMA 328, 1223. https:\/\/doi.org\/10.1001\/jama.2022.16464 (2022).","journal-title":"JAMA"},{"issue":"1","key":"23874_CR24","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1186\/s12885-023-11709-1","volume":"23","author":"Y Wang","year":"2023","unstructured":"Wang, Y., Li, L., Hu, J., Zhao, Y,. Yan, H., Gao, M., Yang, X., Zhang, X., Ma, J., Dai, G. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis, BMC Cancer 23 (2023) 1196. https:\/\/doi.org\/10.1186\/s12885-023-11709-1","journal-title":"BMC Cancer"},{"key":"23874_CR25","doi-asserted-by":"publisher","unstructured":"Yu, H., Chen, P., Cai, X., Chen, C., Zhang, X., He, L., Zhou, Y., Hong, S., Zhang, B., Effi-cacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer, Cancer Immunol. Immunother. CII 71 637\u2013644 (2022). https:\/\/doi.org\/10.1007\/s00262-021-03017-z","DOI":"10.1007\/s00262-021-03017-z"},{"key":"23874_CR26","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.21037\/jtd-23-588","volume":"15","author":"Y Zou","year":"2023","unstructured":"Zou, Y. et al. Efficacy and safety of durvalumab + chemotherapy vs. atezolizumab + chemotherapy in the treatment of small-cell lung cancer: A retrospective comparative cohort study. J. Thorac. Dis. 15, 3339. https:\/\/doi.org\/10.21037\/jtd-23-588 (2023).","journal-title":"J. Thorac. Dis."},{"issue":"1","key":"23874_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13014-023-02308-2.","volume":"18","author":"J Peng","year":"2023","unstructured":"J. Peng, L. Zhang, L. Wang, H. Feng, D. Yao, R. Meng, X. Liu, X. Li, N. Liu, B. Tan, Z. Huang, S. Li, X. Meng, Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer, Radiat. Oncol. Lond. Engl. 18 (2023) 111. https:\/\/doi.org\/10.1186\/s13014-023-02308-2","journal-title":"Radiat. Oncol."},{"key":"23874_CR28","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.21037\/tlcr-24-128","volume":"13","author":"K Misawa","year":"2024","unstructured":"Misawa, K., Watanabe, K., Seike, M. & Hosomi, Y. Durvalumab plus platinum-etoposide chemotherapy for extensive-stage small cell lung cancer: A retrospective real-world study. Transl. Lung Cancer Res. 13, 1585\u20131594. https:\/\/doi.org\/10.21037\/tlcr-24-128 (2024).","journal-title":"Transl. Lung Cancer Res."},{"key":"23874_CR29","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.3390\/curroncol28040270","volume":"28","author":"DE O\u2019Sullivan","year":"2021","unstructured":"O\u2019Sullivan, D. E. et al. Real-world treatment patterns, clinical outcomes, and health care resource utilization in extensive-stage small cell lung cancer in Canada. Curr. Oncol. Tor. Ont. 28, 3091\u20133103. https:\/\/doi.org\/10.3390\/curroncol28040270 (2021).","journal-title":"Curr. Oncol. Tor. Ont."},{"key":"23874_CR30","doi-asserted-by":"publisher","first-page":"1185577","DOI":"10.3389\/fimmu.2023.1185577","volume":"14","author":"B-C Wang","year":"2023","unstructured":"Wang, B.-C., Fu, C. & Lin, G.-H. The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: A survival analysis of reconstructed patient-level data. Front. Immunol. 14, 1185577. https:\/\/doi.org\/10.3389\/fimmu.2023.1185577 (2023).","journal-title":"Front. Immunol."},{"key":"23874_CR31","doi-asserted-by":"publisher","first-page":"978069","DOI":"10.3389\/fonc.2022.978069","volume":"12","author":"H Xia","year":"2022","unstructured":"Xia, H. et al. Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis. Front. Oncol. 12, 978069. https:\/\/doi.org\/10.3389\/fonc.2022.978069 (2022).","journal-title":"Front. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23874-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23874-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23874-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T09:02:46Z","timestamp":1763802166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23874-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23874"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23874-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Review Board of Shandong Cancer Hospital Affiliated with Shandong First Medical University (approval number: SDTHEC 202501065, February 11, 2025), and conducted in accordance with the Declaration of Helsinki. Due to the retrospective design, no separate informed consent was obtained from participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"40167"}}